PCM
ABUS icon

Prelude Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Prelude Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-25,318
Closed -$114K – 1214
2026
Q1 		$114K Hold
25,318
– – 0.01% 1030
2025
Q4 		$122K Hold
25,318
– – 0.01% 1154
2025
Q3 		$115K Hold
25,318
– – 0.01% 1036
2025
Q2 		$78.2K Buy
+25,318
New +$84.1K 0.01% 935
2023
Q3 		– Sell
-18,790
Closed -$43.2K – 1110
2023
Q2 		$43.2K Sell
18,790
-12,409
-40% -$32.3K ﹤0.01% 982
2023
Q1 		$94.5K Sell
31,199
-8,950
-22% -$25.2K 0.01% 957
2022
Q4 		$93.5K Sell
40,149
-13,728
-25% -$32.8K ﹤0.01% 1081
2022
Q3 		$103K Sell
53,877
-14,688
-21% -$34.6K ﹤0.01% 1165
2022
Q2 		$186K Buy
68,565
+9,065
+15% +$23.2K 0.01% 1306
2022
Q1 		$177K Buy
59,500
+15,200
+34% +$46.5K 0.01% 1302
2021
Q4 		$172K Buy
44,300
+5,300
+14% +$20.6K ﹤0.01% 1604
2021
Q3 		$167K Buy
+39,000
New +$130K ﹤0.01% 1404
2021
Q1 		– Sell
-45,100
Closed -$160K – 1504
2020
Q4 		$160K Buy
45,100
+100
+0.2% +$350 ﹤0.01% 1146
2020
Q3 		$141K Buy
+45,000
New +$137K 0.01% 791
2017
Q4 		– Sell
-3,400
Closed -$21K – 1316
2017
Q3 		$21K Buy
+3,400
New +$14.5K ﹤0.01% 1308
2016
Q3 		– Sell
-100
Closed – – 1560
2016
Q2 		$0 Buy
+100
New +$423 ﹤0.01% 1548
2015
Q1 		– Sell
-3,000
Closed -$46K – 1904
2014
Q4 		$46K Buy
+3,000
New +$51.8K 0.01% 1268

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Prelude Capital Management's ABUS Position: Q2 2026 in Review

Prelude Capital Management sold out of Arbutus Biopharma (ABUS) in Q2 2026, closing a stake of 25,318 shares — an estimated $114K sold.

Prelude Capital Management first reported a position in ABUS in Q4 2014 and held it in 17 quarters. The position peaked at $186K in Q2 2022. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Prelude Capital Management reported no remaining Arbutus Biopharma position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 25,318 Arbutus Biopharma shares in Q2 2026, an estimated $114K.
  • Prelude Capital Management first reported a position in Arbutus Biopharma in Q4 2014 and held it in 17 quarters.
  • Prelude Capital Management's Arbutus Biopharma position peaked at $186K in Q2 2022.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.